Protein O‑glucosyltransferase 1 overexpression downregulates p16 in BT474 human breast cancer cells

Jin,Gang; Cao,Zhigang; Sun,Xilin; Wang,Kai; Huang,Tao; Shen,Baozhong

doi:10.3892/ol.2014.2197

Protein O‑glucosyltransferase 1 overexpression downregulates p16 in BT474 human breast cancer cells

Authors:
- Gang Jin
- Zhigang Cao
- Xilin Sun
- Kai Wang
- Tao Huang
- Baozhong Shen
View Affiliations

Affiliations: Department of Medical Imaging, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 28, 2014 https://doi.org/10.3892/ol.2014.2197
Pages: 594-600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein O‑glucosyltransferase 1 (POGLUT1) is a novel gene that was initially isolated and identified from the bone marrow cells of patients with myelodysplastic syndrome/acute myeloid leukemia. Previous findings have suggested that POGLUT1 promotes the proliferation of U937 human tissue lymphoma cells. Furthermore, POGLUT1 has been identified in other tissues, including the mammary glands, lymph nodes, intestine, liver and spleen. In the present study, in order to investigate the function and target of POGLUT1 in BT474 breast cancer cells, the effect of POGLUT1 on cell proliferation, differentiation, apoptosis and key proteins in the transforming growth factor (TGF)‑β1 signaling pathway was investigated in BT474 cells. The overexpression of POGLUT1 in the presence of TGF‑β1 was found to significantly enhance cell viability. Flow cytometric and quantitative polymerase chain reaction analyses revealed that POGLUT1 had an effect on the cell cycle and inhibited the TGF‑β1‑induced transcriptional upregulation of p16, a major cyclin‑dependent kinase inhibitor (CDKI). Furthermore, phosphorylated (p)‑Smad3, which has a key role in mediating the TGF‑β antiproliferative response, was greatly inhibited by exogenous POGLUT1, suggesting a role for POGLUT1 in the TGF‑β1‑mediated signaling pathway in the BT474 cell cycle. However, no significant changes were observed in the expression of other CDKIs or in cell apoptosis. The findings of the present study show that the increase in BT474 cell viabilty induced by POGLUT1 is associated with POGLUT1‑induced inhibition of the transcriptional upregulation of p16 by TGF‑β1, which may be a result of the inhibition of p‑Smad3.

View Figures

View References

1	Takeuchi H, Fernández-Valdivia RC, Caswell DS, Nita-Lazar A, Rana NA, Garner TP, et al: Rumi functions as both a protein O-glucosyltransferase and a protein O-xylosyltransferase. Proc Natl Acad Sci USA. 108:16600–16605. 2011.
2	Fernandez-Valdivia R, Takeuchi H, Samarghandi A, Lopez M, Leonardi J, Haltiwanger RS and Jafar-Nejad H: Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development. 138:1925–1934. 2011.
3	Sethi MK, Buettner FF, Ashikov A, Krylov VB, Takeuchi H, Nifantiev NE, et al: Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J Biol Chem. 287:2739–2748. 2012.
4	Ma W, Du J, Chu Q, Wang Y, Liu L, Song M and Wang W: hCLP46 regulates U937 cell proliferation via Notch signaling pathway. Biochem Biophys Res Commun. 408:84–88. 2011.
5	Teng Y, Liu Q, Ma J, Liu F, Han Z, Wang Y and Wang W: Cloning, expression and characterization of a novel human CAP10-like gene hCLP46 from CD34(+) stem/progenitor cells. Gene. 371:7–15. 2006.
6	Wang Y, Chang N, Zhang T, Liu H, Ma W, Chu Q, et al: Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia. Genet Test Mol Biomarkers. 14:127–133. 2010.
7	Pierelli L, Marone M, Bonanno G, Mozzetti S, Rutella S, Morosetti R, et al: Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. Blood. 95:3001–3009. 2000.
8	Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M and Jackson MW: TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci USA. 108:8668–8673. 2001.
9	Bardeesy N, Morgan J, Sinha M, Signoretti S, Srivastava S, Loda M, et al: Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol. 22:635–643. 2002.
10	Liu P, Zhang C, Feng JB, Zhao YX, Wang XP, Yang JM, et al: Cross talk among Smad, MAPK, and integrin signaling pathways enhances adventitial fibroblast functions activated by transforming growth factor-beta1 and inhibited by Gax. Arterioscler Thromb Vasc Biol. 28:725–731. 2008.
11	Bran GM, Sommer UJ, Goessler UR, Hörmann K, Riedel F and Sadick H: TGF-β1 antisense impacts the SMAD signalling system in fibroblasts from keloid scars. Anticancer Res. 30:3459–3463. 2010.
12	Janknecht R, Wells NJ and Hunter T: TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev. 12:2114–2119. 1998.
13	Kim RH, Wang D, Tsang M, Martin J, Huff C, de Caestecker MP, et al: A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction. Genes Dev. 14:1605–1616. 2000.
14	Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y and Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 92:5545–5549. 1995.
15	McConnell BB, Gregory FJ, Stott FJ, Hara E and Peters G: Induced-expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol. 19:1981–1989. 1999.
16	Aprelikova O, Xiong Y and Liu ET: Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem. 270:18195–18197. 1995.
17	Bockstaele L, Kooken H, Libert F, Paternot S, Dumont JE, de Launoit Y, et al: Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK ‘inhibitors’. Mol Cell Biol. 26:5070–5085. 2006.
18	Noh SJ, Li Y, Xiong Y and Guan KL: Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. Cancer Res. 59:558–564. 1999.
19	Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, et al: p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res. 7:3481–3490. 2001.
20	Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, et al: Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res. 4:1065–1070. 1998.
21	Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, et al: The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 5:4279–4286. 1999.
22	Stein GH, Drullinger LF, Soulard A and Dulić V: Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol. 19:2109–2117. 1999.
23	Akervall J, Bockmühl U, Petersen I, Yang K, Carey TE and Kurnit DM: The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res. 9:1750–1755. 2003.
24	Mihira H, Suzuki HI, Akatsu Y, Yoshimatsu Y, Igarashi T, Miyazono K and Watabe T: TGF-β-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. J Biochem. 151:145–156. 2012.
25	Zhang SJ, Endo S, Ichikawa T, Washiyama K and Kumanishi T: Frequent deletion and 5′ CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res. 58:1231–1237. 1998.
26	Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA. 93:13742–13747. 1996.
27	Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, et al: Alterations of the Cyclin D1/p16-pRB Pathway in mantle cell lymphoma. Cancer Res. 57:4608–4614. 1997.
28	FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, et al: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA. 93:8541–8545. 1996.
29	Cai D, Byth KF and Shapiro GI: AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res. 66:435–444. 2006.
30	Park DS, Morris EJ, Bremner R, Keramaris E, Padmanabhan J, Rosenbaum M, et al: Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage. J Neurosci. 20:3104–3114. 2000.
31	Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J and Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56:5475–5483. 1996.
32	Tsukiyama-Kohara K, Toné S, Maruyama I, Inoue K, Katsume A, Nuriya H, et al: Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem. 279:14531–14541. 2004.
33	Guo K and Walsh K: Inhibition of myogenesis by multiple cyclin-Cdk complexes. Coordinate regulation of myogenesis and cell cycle activity at the level of E2F. J Biol Chem. 272:791–797. 1997.
34	Ojima H, Saito K, Yamauchi H, Yamaki E, Idetu A, Hosouchi Y, Nishida Y, et al: P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res. 26:933–937. 2006.
35	Alani RM, Young AZ and Shifflett CB: Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA. 98:7812–7816. 2001.
36	Yuen PW, Man M, Lam KY and Kwong YL: Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol. 55:58–60. 2002.
37	Singh RP, Agarwal C and Agarwal R: Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis. 24:555–563. 2003.